Drugs / vCP1452
vCP1452
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00006495 | ? → Sep 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000904 | ? → Aug 1999 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00219362 | Apr 2004 → Nov 2005 | HIV infectious disease | Objectif Recherche Vaccins SIDA | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vCP1452 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00219362 ↗ |
| Known as | ALVAC(2)120(B,MN)GNP | “ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00006495 ↗1“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00000904 ↗ |
| Known as | ALVAC-HIV | “Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).” PMID 18580611 ↗ Jul 2008 |
| Modality | Vaccine | “therapeutic immunizations with HIV-1 immunogen and vCP1452” NCT00006495 ↗ |
| Route | Intramuscular | “The immunization will be administered by intramuscular injection” NCT00219362 ↗ |